skip to main content

Severe hypertriglyceridemia in advanced chronic kidney disease — ABIM Board MCQ

Instant feedback + full explanation. One question, done properly.

HardLipidsSevere hypertriglyceridemia in advanced chronic kidney diseaseABIM Board

A 64-year-old man with type 2 diabetes mellitus, hypertension, and stage 4 chronic kidney disease is evaluated for dyslipidemia. He takes atorvastatin 40 mg daily and reports consistent adherence. He has no abdominal pain, nausea, or vomiting. The fasting triglyceride level is 1,260 mg/dL, confirmed at 1,190 mg/dL 1 week later; HDL-C is 29 mg/dL, and the LDL-C level cannot be calculated. Hemoglobin A1c is 10.4%, estimated glomerular filtration rate is 24 mL/min/1.73 m², serum lipase is normal, and thyroid-stimulating hormone is normal. He does not drink alcohol. A very-low-fat diet and intensified diabetes treatment are initiated. Which of the following is the most appropriate lipid-lowering pharmacologic strategy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Continue atorvastatin and add icosapent ethyl 2 g twice daily

Triglyceride levels above 1,000 mg/dL indicate chylomicronemia and substantial pancreatitis risk, requiring prompt triglyceride-directed management even without current pancreatitis. Management includes a very-low-fat diet, correction of secondary drivers such as uncontrolled diabetes, and prescription omega-3 fatty acids. Icosapent ethyl is appropriate for severe hypertriglyceridemia and does not have the renal contraindication or statin interaction that limits fibrate use here. Atorvastatin should be continued for ASCVD prevention in this high-risk patient. Fenofibrate is ordinarily a reasonable near-miss for severe hypertriglyceridemia, but the specified full dose is inappropriate and fibrates should be avoided in severe renal dysfunction. Gemfibrozil should not be combined with a statin because this combination substantially increases muscle-toxicity risk. Ezetimibe lowers LDL-C but does not provide the triglyceride reduction needed to address this patient's immediate pancreatitis risk. Increasing atorvastatin may improve ASCVD risk and modestly lower triglycerides, but statin intensification alone is inadequate at a triglyceride level exceeding 1,000 mg/dL. A normal lipase level and absence of abdominal symptoms indicate that acute pancreatitis is not currently present; they do not remove the need for urgent preventive treatment.

Reference: ACC Consensus on ASCVD Risk Reduction in Hypertriglyceridemia: Key Points (July 27, 2021) — https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2021/07/27/21/04/2021-ACC-ECDP-Hypertriglyceridemia American College of Cardiology Lipid Manager (Current tool, accessed August 27, 2026) — https://tools.acc.org/LDL/ 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia (May 2026) — https://learn.acc.org/AssetListing/2026-ACC-AHA-AACVPR-ABC-ACPM-ADA-AGS-APhA-ASPC-NLA-PCNA-Guideline-on-the-Management-of-Dyslipidemia-JACC-May-2026-2-26357/Article-ACC-AHA-AACVPR-ABC-ACPM-ADA-AGS-APhA-ASPC-NLA-PCNA-Guideline-on-the-Management-of-Dyslipidemia-36357